Novartis AG said Saturday that its cancer drug, Kymriah, has received authorization from the Food and Drug Administration to be used in the treatment of relapsed or refractory follicular lymphoma in adults.
The Swiss pharma company said the approval is the third use or indication of use the drug has received from the FDA for use in different types of diseases. "In accordance with the Accelerated Approval Program, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s)," the company said.
Kymriah was already approved in the European Union for relapsed or refractory follicular lymphoma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.